DGX
Quest Diagnostics Incorporated
DGX has slightly lower modeled downside risk, despite its lower overall score.
LLY
Eli Lilly and Company
LLY has the edge over DGX overall, supported by stronger valuation and stronger modeled upside.
DGX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Stable |
DGX's revenue, profitability and cash flow are currently healthy, and its balance sheet is stable.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
DGX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $102 | -61% |
| Fair | 19x | $192 | -26% |
| Expensive | 22x | $220 | -15% |
| Forward | 22x | $260 | — |
| Current | 26x | $260 | — |
Historical ranges are pointers, not guarantees.
DGX has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
DGX Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for DGX, with profitability holding steady.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over DGX on the outlook, with more favorable profitability expectations.
DGX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $11.60 | +16% |
| Q3 2026 | $10.04 | +18% |
| Q2 2026 | $9.42 | +13% |
| Q1 2026 | $9.05 | +14% |
| Q4 2025 | $8.75 | +14% |
| Q3 2025 | $8.52 | +15% |
| Q2 2025 | $8.35 | +13% |
| Q1 2025 | $7.91 | +6.5% |
| Q4 2024 | $7.69 | +2.7% |
DGX's earnings per share have fallen from their peak: $10.04 over the past year, against $16.77 in mid-2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over DGX on earnings, with stronger typical year-over-year growth.
DGX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.1B | +10% |
| Q2 2026 | $3B | +10% |
| Q1 2026 | $2.9B | +9.2% |
| Q4 2025 | $2.8B | +7.1% |
| Q3 2025 | $2.8B | +13% |
| Q2 2025 | $2.8B | +15% |
| Q1 2025 | $2.7B | +12% |
| Q4 2024 | $2.6B | +15% |
DGX's revenue has grown year over year for 11 quarters in a row: $3.1B last quarter, up 10% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 15% | +1.8 points |
| Q2 2026 | 15% | -0.8 points |
| Q1 2026 | 14% | +0.7 points |
| Q4 2025 | 14% | 0 points |
| Q3 2025 | 14% | +0.5 points |
| Q2 2025 | 16% | +1 points |
| Q1 2025 | 13% | +0.4 points |
| Q4 2024 | 14% | +2.1 points |
DGX's operating margin was 15% last quarter, up 1.8 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over DGX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over DGX on profitability, with a higher operating margin.
DGX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $445M | +6.2% |
| Q2 2026 | $459M | +5.3% |
| Q1 2026 | $164M | -17% |
| Q4 2025 | $307M | -10% |
| Q3 2025 | $419M | +68% |
| Q2 2025 | $436M | +63% |
| Q1 2025 | $197M | +294% |
| Q4 2024 | $341M | -25% |
DGX still generates free cash flow, though less than at its 2020 peak: $1.4B over the past year.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over DGX on cash flow, with more consistent year-over-year improvement.
DGX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | -0.9% | -1M shares |
| 3 years | -1.8% | -2M shares |
| 5 years | -10% | -13M shares |
| Available history | -18% | -24M shares |
DGX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $150M |
| Q4 2025 | $300M |
| Q4 2023 | $275M |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | $461M |
| Q3 2022 | $374M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
DGX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 2.3x | Moderate |
| Q1 2026 | 2.4x | Moderate |
| Q4 2025 | 2.5x | Moderate |
| Q3 2025 | 2.5x | Moderate |
| Q2 2025 | 2.7x | Moderate |
| Q1 2025 | 3.0x | Moderate |
| Q4 2024 | 3.1x | Elevated |
DGX's net debt is about 2.1 years of its operating earnings (EBITDA), down from 2.5 years a year ago.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY has the edge over DGX on leverage, with a lower net debt burden relative to earnings.
DGX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 70.0 | Neutral |
| Stochastic | 89.7 | Overbought |
DGX's weekly RSI is 70 (neutral) and its Stochastic is 90 (overbought).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
DGX PE vs Healthcare Sector
| Metric | DGX | Sector median | Relative |
|---|---|---|---|
| PE | 26x | 26x | Same PE |
| PE % | 99 | 29 | 70 pts above |
DGX has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
DGX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $243.1 | 6.8% above |
| 20 week MA | $235.9 | 10% above |
| 50 week MA | $209.8 | 24% above |
| 100 week MA | $191.5 | 36% above |
| 200 week MA | $165.4 | 57% above |
DGX is in an uptrend: it's above all five of its weekly moving averages, and 57% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
DGX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $106.9 | $120.2 | +13% |
| 2021 | $120.2 | $167.1 | +39% |
| 2022 | $167.1 | $156.3 | -6.4% |
| 2023 | $156.3 | $137.9 | -12% |
| 2024 | $137.9 | $152.6 | +11% |
| 2025 | $152.6 | $175.9 | +15% |
| 2026 YTD | $175.9 | $259.7 | +48% |
DGX has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.